Central Diabetes Insipidus: A Previously Unreported Side Effect of Temozolomide

作者：Faje Alexander T^*; Nachtigall Lisa; Wexler Deborah; Miller Karen K; Klibanski Anne; Makimura Hideo

来源：Journal of Clinical Endocrinology & Metabolism, 2013, 98(10): 3926-3931.

DOI：10.1210/jc.2013-2435

Context: Temozolomide ( TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system. We describe 2 patients with apparent TMZ-induced central diabetes insipidus. Using our institution's Research Patient Database Registry, we identified 3 additional potential cases of TMZ-induced diabetes insipidus among a group of 1545 patients treated with TMZ.
Case Presentations: A 53-year-old male with an oligoastrocytoma and a 38-year-old male with an oligodendroglioma each developed symptoms of polydipsia and polyuria approximately 2 months after the initiation of TMZ. Laboratory analyses demonstrated hypernatremia and urinary concentrating defects, consistent with the presence of diabetes insipidus, and the patients were successfully treated with desmopressin acetate. Desmopressin acetate was withdrawn after the discontinuation of TMZ, and diabetes insipidus did not recur. Magnetic resonance imaging of the pituitary and hypothalamus was unremarkable apart from the absence of a posterior pituitary bright spot in both of the cases. Anterior pituitary function tests were normal in both cases. Using the Research Patient Database Registry database, we identified the 2 index cases and 3 additional potential cases of diabetes insipidus for an estimated prevalence of 0.3% ( 5 cases of diabetes insipidus per 1545 patients prescribed TMZ).
Conclusions: Central diabetes insipidus is a rare but reversible side effect of treatment with TMZ.

• 出版日期2013-10